ISPOR 19TH ANNUAL EUROPEAN CONGRESS ISSUE PANEL EXPLORES ISSUE OF ADAPTIVE PATHWAYS AND PATIENT ACCESS

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel this afternoon entitled, Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? The session took place at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Jacoline Bouvy, PhD, Scientific Adviser, National Institute for Health and Care Excellence, London, UK. Speakers for the session included:
  • Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicine Agency, London, UK
  • Ad Schuurman, MSc, MBA, President of MEDEV, Zorginstituut Nederland, Diemen, The Netherlands
  • Claudine Sapede, PharmD, MSc, Global HTA and Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland
This panel explored the use of adaptive pathways in the development medicines. Speakers noted that adaptive pathways could help patients gain earlier access to promising treatments in areas of high unmet medical needs, but acknowledged that this approach may also have implications for access decisions at the national and regional levels that need to be explored. Jacoline Bouvy, PhD provided an overview of ADAPT SMART, the enabling platform for the coordination of Medicines Adaptive Pathways for Patients (MAPPs) activities. MAPPS seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product lifespan in a sustainable fashion. Hans-Georg Eichler, MD, MSc discussed the regulatory viewpoint on adaptive pathways, and Ad Schuurman, MSc, MBA and Claudine Sapede, PharmD, MSc provided perspectives from the payer and industry sectors, respectively. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Chief Science Officer Dr Laura Pizzi Named to NJBIZ's 2026 People to Watch in Healthcare List

Jul 29, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) is proud to announce its Chief Science Officer, Laura Pizzi, PharmD, MPH, has been recognized by NJBIZ as one of its 2026 People to Watch in Healthcare.

ISPOR Publishes White Paper Focused on Systemic Coherence for Healthcare Decision Making in Europe

Jul 21, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has released a new white paper, “Achieving Systemic Coherence for Healthcare Decision Making in Europe.”

ISPOR Announces the Healthcare Investment Summit 2026

Jul 20, 2026

ISPOR announced their inaugural Healthcare Investment Summit 2026, which will bring together healthcare investors, founders, pharma and device executives, policy experts, health economists, and access leaders on September 22–23, 2026, in San Francisco to examine the critical factors shaping investment decisions across the healthcare landscape.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×